What Bioskin does

Eurofins bioskin (Bioskin GmbH) is a full-service Contract Research Organization (CRO) specialized exclusively in dermatology and aesthetics, founded in 1992 and headquartered in Hamburg, Germany. The company plans and conducts clinical trials for pharmaceutical, cosmetics, and personal care companies developing dermatological products, with service coverage spanning regulatory consulting, early-phase human safety studies, Proof-of-Concept efficacy testing, vasoconstrictor assays, biophysical measurement methods, and global Phase II-IV multicenter multinational trials for new chemical entities, new formulations with known actives, and generics. It also operates a dedicated Research Center Dermatology, clinical project management, monitoring and medical monitoring, data operations (data management and statistics), quality management, and medical writing under ISO 14155:2020 certified operations.

Underlying capabilities are methodological rather than platform-tech: Bioskin's differentiation rests on specialized dermatology-tailored experimental techniques (vasoconstrictor assays, biophysical skin-property measurement, human safety readouts) integrated with regulatory consulting for dermatology-specific submission pathways. Service delivery is anchored in a Hamburg research center combined with international partnering arrangements for cross-border trial execution, with the company operating as a wholly-owned subsidiary of Eurofins Scientific SE (Euronext Paris: ERF). Headcount is reported at 51-100 employees.

The business model is B2B professional services revenue, with quote-based, project-specific pricing across four main streams: clinical development services (Phase II-IV trials), regulatory consulting, dedicated research center capacity, and data operations/medical writing. Customer segmentation is vertical: pharmaceutical companies (NCEs, reformulations, generics) form one primary segment, and cosmetics/personal care companies requiring dermatological safety and efficacy validation form the second. Go-to-market is sales-led through direct engagement with sponsor R&D teams, supported by Eurofins' corporate marketing channels and professional networks; customers are not publicly disclosed and the company has no consumer-facing distribution, app, public API, or SDK.

Name

Bioskin

Legal name

Bioskin GmbH

Website

https://bioskincro.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

51–100 employees

Short description

Eurofins bioskin (Bioskin GmbH) is a Hamburg-based, full-service dermatology-specialized CRO conducting Phase II-IV trials, regulatory consulting, early-phase safety and Proof-of-Concept studies, and biophysical efficacy testing for pharmaceutical, cosmetics, and personal care sponsors globally as a wholly-owned subsidiary of Eurofins Scientific SE.

Ownership category

akta.pro rank

Product category

Contract Research Organization (Dermatology Clinical Trials)

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Dermatology clinical trials
• Clinical research organization
• Regulatory consulting dermatology
• Pharmaceutical trial services
• Cosmetics clinical testing

Headquarters

HQ city

Hamburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Development Services: Fees for conducting Phase II-IV clinical trials for dermatological products including NCEs, new formulations with known actives, and generics. Services include safety testing, efficacy testing/Proof-of-Concept, multicenter multinational trials.
2. Regulatory Consulting: Strategic and regulatory consulting services for dermatology and related products
3. Research Center Dermatology Services: Specialized dermatology research center providing clinical study capabilities and infrastructure
4. Data Operations and Medical Writing: Data management, statistics, and medical writing services supporting clinical trials

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Eurofins bioskin is a full-service Contract Research Organization (CRO) specialized in dermatology, providing strategic and regulatory consulting, early-phase human safety and Proof-of-Concept studies, vasoconstrictor assays, and global Phase II-IV multicenter multinational trials for new chemical entities, new formulations with known actives, generics, and aesthetic dermatology products. Services are delivered for pharmaceutical companies, cosmetics, and personal care companies developing dermatological products, supported by a dedicated dermatology research center, clinical project management, monitoring, medical monitoring, data operations, quality management, and medical writing.

Product overview

Eurofins bioskin is a full-service CRO (Contract Research Organization) specialized in dermatology offering an integrated portfolio of services. The company provides strategic and regulatory consulting for dermatology and related products, early phase human safety and Proof-of-Concept studies, vasoconstrictor assays, and global Phase II-IV trials for NCEs, new formulations with known actives, and generics. The service portfolio spans Clinical Development (including Safety, Efficacy Testing, Multicenter Multinational Trials, Generics, International Partnering, Aesthetics, and Biophysical Measurement Methods), Research Center Dermatology, Clinical Project Management, Monitoring, Medical Monitoring, Data Operations (Data Management and Statistics), Quality Management, and Medical Writing. The services are designed to work together as an integrated offering for pharmaceutical and cosmetics companies conducting dermatology clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Dermatologic Consulting and Regulatory
• Clinical Development
• Research Center Dermatology
• Clinical Project Management
• Monitoring
• Medical Monitoring
• Data Operations
• Quality Management
• Medical Writing
• Vasoconstrictor Assays

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Eurofins GroupcoreStrategic or Co-development PartnerBioskin operates as a subsidiary of Eurofins Group, a global leader in bioanalytics testing. This affiliation provides access to Eurofins' broader laboratory infrastructure, regulatory expertise, and international network while maintaining specialized focus on dermatological clinical research.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Biorasi: Biorasi is a dermatology-focused CRO running clinical programs for skin and aesthetic indications. Like Bioskin it competes for the same niche sponsors seeking therapeutic-area depth over scale.
• Proinnovera: Proinnovera is a German-based dermatology CRO offering clinical trial services for skin and aesthetic products. Geographically and therapeutically, it is one of Bioskin's closest competitors in Europe.
• Novum Pharmaceutical Research Services: Novum is a US-based dermatology-specialized CRO with a similar Phase II–IV service profile. It competes head-to-head with Bioskin for North American and global dermatology sponsors.

Broad incumbents

• IQVIA: IQVIA is the world's largest CRO with a broad dermatology practice. It competes with Bioskin on Phase III dermatology programs and uses its scale to bid down specialty CROs.
• Parexel International: Parexel is a top-5 global CRO with active dermatology and aesthetics business. It is a frequent alternative when sponsors consolidate work with large generalist providers.
• ICON plc: ICON is a major global CRO with therapeutic-area breadth including dermatology. It competes for the same Phase II–IV dermatology RFPs as Bioskin, especially in larger pivotal programs.
• Medpace: Medpace is a mid-to-large global CRO with growing dermatology exposure. Its full-service model and therapeutic-area teams compete with Bioskin for sponsor mindshare in dermatology.
• Syneos Health: Syneos Health is a global biopharma solutions organization offering CRO services including dermatology. It is a competitor for integrated clinical development work in skin indications.
• Charles River Laboratories: Charles River is a global CRO/CDMO with a sizable clinical services business that touches dermatology sponsors. It competes on the broader Phase II–IV dermatology RFP set.

Emerging players

• TFS International: TFS International is a mid-sized global CRO with growing dermatology and aesthetics work. It is a comparable-sized specialist expanding into the same niche.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bioskin-gmbh

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioskin